Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pharmaceutical Design
  4. Volume 31, Issue 1
  5. Article
Volume 31, Issue 1
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

A double bond between the nitrogen and carbon atoms characterizes a wide class of compounds known as Schiff bases. The flexibility of Schiff bases is formed from several methods and may be combined with alkyl or aryl substituents. The group is a part of organic compounds, either synthetic or natural, and it serves as a precursor and an intermediate in drugs that have therapeutic action. The review focuses on molecular docking and structure-activity relationship (SAR) analysis for antidiabetic effects of the different non-metal Schiff bases. Many studies have found that Schiff bases are used as linkers in an extensive range of synthesized compounds and other activities. Thus, this current study aims to give the scientific community a thoughtful look at the principal ideas put forward by investigators regarding antidiabetic actions exhibited by certain Schiff-based derivatives, as this review covered many aspects, including docking and SAR analysis. For individuals who intend to create novel antidiabetic compounds with Schiff bases as pharmacophores or physiologically active moieties, it will be an invaluable informational resource.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128339161240913055034
2024-09-20
2025-06-21

  • From This Site

    /content/journals/cpd/10.2174/0113816128339161240913055034
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. QinW. LongS. PanunzioM. BiondiS. Schiff bases: A short survey on an evergreen chemistry tool.Molecules20131810122641228910.3390/molecules181012264 24108395
     [Google Scholar]
  2. HameedA. al-RashidaM. UroosM. Abid AliS. KhanK.M. Schiff bases in medicinal chemistry: A patent review (2010-2015).Expert Opin. Ther. Pat.2017271637910.1080/13543776.2017.1252752 27774821
     [Google Scholar]
  3. MurtazaG. MumtazA. KhanF.A. Recent pharmacological advancements in Schiff bases: A review.Acta Pol. Pharm.2014714531535 25272879
     [Google Scholar]
  4. GulS AlamA Zainab, et al. Exploring the synthesis, molecular structure and biological activities of novel Bis-Schiff base derivatives: A combined theoretical and experimental approach.J. Mol. Struct.2024130613782810.1016/j.molstruc.2024.137828
     [Google Scholar]
  5. KarthikS. GomathiT. PriyaP. Synthesis, characterization, antimicrobial, anti-diabetic, anti-inflammatory and anti-cancer studies of Schiff base metal (II) complexes derived from mixed Schiff base ligand.Indian J. Chem.2024631112120
     [Google Scholar]
  6. SahuR. ShahK. Schiff bases: A captivating scaffold with potential anticonvulsant activity.Mini Rev. Med. Chem.202424181632165010.2174/0113895575302197240408121537 38629363
     [Google Scholar]
  7. ZehraS. Shavez KhanM. AhmadI. ArjmandF. New tailored substituted benzothiazole Schiff base Cu(II)/Zn(II) antitumor drug entities: Effect of substituents on DNA binding profile, antimicrobial and cytotoxic activity.J. Biomol. Struct. Dyn.20193771863187910.1080/07391102.2018.1467794 29676660
     [Google Scholar]
  8. ŞahinS. DegeN. Synthesis, characterization, X-ray, HOMO-LUMO, MEP, FT-IR, NLO, Hirshfeld surface, ADMET, boiled-egg model properties and molecular docking studies with human cyclophilin D (CypD) of a Schiff base compound: (E)-1-(5-nitro-2-(piperidin-1-yl)phenyl)-N-(3-nitrophenyl)methanimine.Polyhedron202120511532010.1016/j.poly.2021.115320
     [Google Scholar]
  9. YadavG. ManiJ.V. Green synthesis of Schiff bases by using natural acid catalysts.Int. J. Sci. Res.201542121127
     [Google Scholar]
  10. Al ZoubiW. Biological activities of Schiff bases and their complexes: A review of recent works.Int J Org Chem (Irvine)20132013
     [Google Scholar]
  11. RaczukE. DmochowskaB. Samaszko-FiertekJ. MadajJ. Different Schiff bases-structure, importance, and classification.Molecules202227378710.3390/molecules27030787 35164049
     [Google Scholar]
  12. KhanM.I. GulS. KhanM.A. Schiff bases and their metallic derivatives: Highly versatile molecules with biological and abiological perspective.In: Stability and Applications of Coordination Compounds.IntechOpen2019
     [Google Scholar]
  13. CatalanoA. IacopettaD. PellegrinoM. AquaroS. FranchiniC. SinicropiM.S. Diarylureas: Repositioning from antitumor to antimicrobials or multi-target agents against new pandemics.Antibiotics (Basel)20211019210.3390/antibiotics10010092 33477901
     [Google Scholar]
  14. AlkahtaniH.M. AlmehiziaA.A. Al-OmarM.A. In vitro evaluation and bioinformatics analysis of Schiff bases bearing pyrazole scaffold as bioactive agents: Antioxidant, anti-diabetic, anti-Alzheimer, and anti-arthritic.Molecules20232820712510.3390/molecules28207125 37894604
     [Google Scholar]
  15. JamilW. ShaikhJ. YousufM. TahaM. KhanK.M. ShahS.A.A. Synthesis, anti-diabetic and in silico QSAR analysis of flavone hydrazide Schiff base derivatives.J. Biomol. Struct. Dyn.20224023127231273810.1080/07391102.2021.1975565 34514955
     [Google Scholar]
  16. KumarA. Salahuddin MazumderA. KumarR. Synthesis, characterization, and antidiabetic evaluation of substituted 5-(2-chloro-quinolin-3-ylmethylene)-thiazolidine-2, 4-dione.Indian J. Heterocycl. Chem.202131357364
     [Google Scholar]
  17. AdalatB. RahimF. TahaM. Synthesis of Benzofuran–based Schiff bases as anti-diabetic compounds and their molecular docking studies.J. Mol. Struct.2022126513328710.1016/j.molstruc.2022.133287
     [Google Scholar]
  18. IacopettaD. CeramellaJ. CatalanoA. Schiff bases: Interesting scaffolds with promising antitumoral properties.Appl. Sci. (Basel)2021114187710.3390/app11041877
     [Google Scholar]
  19. AshoorL.S. MohaisenI.K. Al-ShemaryR.K. A review on versatile applications of transition metal complexes incorporating Schiff bases from amoxicillin and cephalexin.Eur Asian J BioSci202014275417550
     [Google Scholar]
  20. AdesinaA.D. Synthesis of Schiff bases by non-conventional methods.In: Schiff Base in Organic.Inorganic and Physical Chemistry. IntechOpen202210.5772/intechopen.108688
     [Google Scholar]
  21. FontanaR. MarconiP.C.R. CaputoA. GavalyanV.B. Novel chitosan-based Schiff base compounds: Chemical characterization and antimicrobial activity.Molecules2022279274010.3390/molecules27092740 35566088
     [Google Scholar]
  22. CeramellaJ. IacopettaD. CatalanoA. CirilloF. LappanoR. SinicropiM.S. A review on the antimicrobial activity of Schiff bases: Data collection and recent studies.Antibiotics (Basel)202211219110.3390/antibiotics11020191 35203793
     [Google Scholar]
  23. LakshmiS.S. GeethaK. GayathriM. ShanmugamG. Synthesis, crystal structures, spectroscopic characterization and in vitro antidiabetic studies of new Schiff base Copper(II) complexes.J. Chem. Sci.201612871095110210.1007/s12039‑016‑1099‑8
     [Google Scholar]
  24. LiT. PangH. WuQ. Rigid Schiff base complex supermolecular aggregates as a high-performance pH probe: Study on the enhancement of the aggregation-caused quenching (ACQ) effect via the substitution of halogen atoms.Int. J. Mol. Sci.20222311625910.3390/ijms23116259 35682938
     [Google Scholar]
  25. KapoorG. PathakD.P. BhutaniR. HusainA. JainS. IqbalM.A. Synthesis, ADME, docking studies and in vivo anti-hyperglycaemic potential estimation of novel Schiff base derivatives from octadec-9-enoic acid.Bioorg. Chem.20198447849210.1016/j.bioorg.2018.12.004 30579158
     [Google Scholar]
  26. TobiasD.K. MerinoJ. AhmadA. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine.Nat. Med.202329102438245710.1038/s41591‑023‑02502‑5 37794253
     [Google Scholar]
  27. Diabetes in South-East Asia.Available from: https://www.who.int/southeastasia/health-topics/diabetes (accessed on 9-9-2024)
     [Google Scholar]
  28. LinY. ShengH. TingT.H. Molecular and clinical characteristics of monogenic diabetes mellitus in southern Chinese children with onset before 3 years of age.BMJ Open Diabetes Res. Care202081e00134510.1136/bmjdrc‑2020‑001345 32792356
     [Google Scholar]
  29. GanesanK. RanaM.B. SultanS. Oral Hypoglycemic Medications.In: StatPearls.StatPearls Publishing2023
     [Google Scholar]
  30. JoungK.I. JungG.W. ParkH.H. LeeH. ParkS.H. ShinJ.Y. Gender differences in adverse event reports associated with antidiabetic drugs.Sci. Rep.20201011754510.1038/s41598‑020‑74000‑4 33067519
     [Google Scholar]
  31. KumarA Salahuddin, Kumar R, et al. Anti-diabetic potentials of thiazolidinedione analogues with efficient synthetic procedures: A review of literature.Mini Rev. Org. Chem.2022191305110.2174/1570193X18666210224153849
     [Google Scholar]
  32. BoccardiA. ShubrookJ.H. Cutaneous reactions to antidiabetic agents: A narrative review.Diabetology (Basel)2022319710710.3390/diabetology3010008
     [Google Scholar]
  33. LeonardC.E. HanX. BrensingerC.M. Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study.Pharmacoepidemiol. Drug Saf.201827191810.1002/pds.4337 29108130
     [Google Scholar]
  34. León-GonzálezA.J. Jiménez-VacasJ.M. Fuentes-FayosA.C. Role of metformin and other metabolic drugs in the prevention and therapy of endocrine-related cancers.Curr. Opin. Pharmacol.202160172610.1016/j.coph.2021.06.002 34311387
     [Google Scholar]
  35. RosaM.M. DiasT. Commonly used endocrine drugs.Handb. Clin. Neurol.201412080982410.1016/B978‑0‑7020‑4087‑0.00054‑1 24365354
     [Google Scholar]
  36. Buformin.Available from: https://go.drugbank.com/drugs/DB04830 (accessed on 9-9-2024)
  37. Phenformin.Available from: https://go.drugbank.com/drugs/DB00914 (accessed on 9-9-2024)
  38. ChiassonJ.L. JosseR.G. GomisR. HanefeldM. KarasikA. LaaksoM. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial.JAMA2003290448649410.1001/jama.290.4.486 12876091
     [Google Scholar]
  39. KawamoriR. TajimaN. IwamotoY. KashiwagiA. ShimamotoK. KakuK. Voglibose for prevention of type 2 diabetes mellitus: A randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.Lancet200937396751607161410.1016/S0140‑6736(09)60222‑1 19395079
     [Google Scholar]
  40. GulS. JanF. AlamA. Synthesis, molecular docking and DFT analysis of novel bis-Schiff base derivatives with thiobarbituric acid for α-glucosidase inhibition assessment.Sci. Rep.2024141341910.1038/s41598‑024‑54021‑z 38341468
     [Google Scholar]
  41. AliZ RehmanW RasheedL New 1,3,4-thiadiazole derivatives as α-glucosidase inhibitors: Design, synthesis, DFT, ADME, and in vitro enzymatic studies.ACS Omega202497acsomega.3c0585410.1021/acsomega.3c05854 38405480
     [Google Scholar]
  42. TahaM. GilaniS.J. KazmiI. Synthesis, biological evaluation and molecular docking study of indazole based Schiff base analogues as new anti-diabetic inhibitors.J. Mol. Struct.2024130013718910.1016/j.molstruc.2023.137189
     [Google Scholar]
  43. PashaA.R. KhanA. UllahS. Synthesis of new diphenyl urea-clubbed imine analogs and its implications in diabetic management through in vitro and in silico approaches.Sci. Rep.2023131187710.1038/s41598‑023‑28828‑1 36725861
     [Google Scholar]
  44. TariqH.Z. SaeedA. UllahS. Synthesis of novel coumarin–hydrazone hybrids as α-glucosidase inhibitors and their molecular docking studies.RSC Advances20231337262292623810.1039/D3RA03953F 37670997
     [Google Scholar]
  45. ShayeganN. HaghipourS. TanidehN. Synthesis, in vitro α-glucosidase inhibitory activities, and molecular dynamic simulations of novel 4-hydroxyquinolinone-hydrazones as potential antidiabetic agents.Sci. Rep.2023131630410.1038/s41598‑023‑32889‑7 37072431
     [Google Scholar]
  46. DaudS. AbidO-R. RehmanW. In vitro evaluation of novel mefenamic acid derivatives as potential α-glucosidase and urease inhibitors: Design, synthesis, in silico and cytotoxic studies.J. Saudi Chem. Soc.202327410168010.1016/j.jscs.2023.101680
     [Google Scholar]
  47. HayatS. UllahH. RahimF. Synthesis, biological evaluation and molecular docking study of benzimidazole derivatives as α-glucosidase inhibitors and anti-diabetes candidates.J. Mol. Struct.2023127613477410.1016/j.molstruc.2022.134774
     [Google Scholar]
  48. UllahH. UddinI. KhanF. HussainR. KhanS. Synthesis, in vitro α-glucosidase, urease activities and molecular docking study of benzoxazole bearing Schiff base derivatives.Chemical Data Collections20234610105410.1016/j.cdc.2023.101054
     [Google Scholar]
  49. TokalıF.S. TaslimiP. SadeghiM. ŞenolH. Synthesis and evaluation of quinazolin-4(3H)-one derivatives as multitarget metabolic enzyme inhibitors: A biochemistry-oriented drug design.ChemistrySelect2023825e20230115810.1002/slct.202301158
     [Google Scholar]
  50. FanM. YangW. LiuL. PengZ. HeY. WangG. Design, synthesis, biological evaluation, and docking study of chromone-based phenylhydrazone and benzoylhydrazone derivatives as antidiabetic agents targeting α-glucosidase.Bioorg. Chem.202313210638410.1016/j.bioorg.2023.106384 36696731
     [Google Scholar]
  51. AlharthyR.D. ZahraS.B. FatimaN. Synthesis and biological evaluation of novel isatin-hydrazide conjugates as potential antidiabetic agents.J. Mol. Struct.2023128813578310.1016/j.molstruc.2023.135783
     [Google Scholar]
  52. KhanI. RehmanW. RahimF. Synthesis, in vitro α-glucosidase inhibitory activity and molecular docking study of new benzotriazole-based bis-Schiff base derivatives.Pharmaceuticals (Basel)20221611710.3390/ph16010017 36678514
     [Google Scholar]
  53. KaurR. KumarR. DograN. YadavA.K. Design, synthesis, biological evaluations and in silico studies of sulfonate ester derivatives of 2-(2-benzylidenehydrazono)thiazolidin-4-one as potential α-glucosidase inhibitors.J. Mol. Struct.2022124713126610.1016/j.molstruc.2021.131266
     [Google Scholar]
  54. PedroodK. RezaeiZ. KhavaninzadehK. Design, synthesis, and molecular docking studies of diphenylquinoxaline-6-carbohydrazide hybrids as potent α-glucosidase inhibitors.BMC Chem.20221615710.1186/s13065‑022‑00848‑4 35909126
     [Google Scholar]
  55. AskarzadehM. AzizianH. AdibM. Design, synthesis, in vitro α-glucosidase inhibition, docking, and molecular dynamics of new phthalimide-benzenesulfonamide hybrids for targeting type 2 diabetes.Sci. Rep.20221211056910.1038/s41598‑022‑14896‑2 35732907
     [Google Scholar]
  56. KarrouchiK. FettachS. TamerÖ. Synthesis, crystal structure, spectroscopic characterization, α-glucosidase inhibition and computational studies of (E)-5-methyl-N′-(pyridin-2-ylmethylene)-1H-pyrazole-3-carbohydrazide.J. Mol. Struct.2022124813150610.1016/j.molstruc.2021.131506
     [Google Scholar]
  57. TokF. KüçükalB. BaltaşN. Tatar YılmazG. Koçyiğit-KaymakçıoğluB. Synthesis of novel thiosemicarbazone derivatives as antidiabetic agent with enzyme kinetic studies and antioxidant activity.Phosphorus Sulfur Silicon Relat. Elem.2022197121284129410.1080/10426507.2022.2099857
     [Google Scholar]
  58. TokalıF.S. TaslimiP. UsanmazH. KaramanM. ŞendilK. Synthesis, characterization, biological activity and molecular docking studies of novel schiff bases derived from thiosemicarbazide: Biochemical and computational approach.J. Mol. Struct.2021123112966610.1016/j.molstruc.2020.129666
     [Google Scholar]
  59. BushraShamim S Khan KM, et al. Synthesis, in vitro, and in silico evaluation of Indazole Schiff bases as potential α-glucosidase inhibitors.J. Mol. Struct.2021124213082610.1016/j.molstruc.2021.130826
     [Google Scholar]
  60. Shareghi-BoroujeniD. IrajiA. MojtabaviS. FaramarziM.A. AkbarzadehT. SaeediM. Synthesis, in vitro evaluation, and molecular docking studies of novel hydrazineylideneindolinone linked to phenoxymethyl-1,2,3-triazole derivatives as potential α-glucosidase inhibitors.Bioorg. Chem.202111110486910.1016/j.bioorg.2021.104869 33839583
     [Google Scholar]
  61. RafiqK. KhanM. MuhammedN. New amino acid clubbed Schiff bases inhibit carbonic anhydrase II, α-glucosidase, and urease enzymes: In silico and in vitro.Med. Chem. Res.202130371272810.1007/s00044‑020‑02696‑0
     [Google Scholar]
  62. AzimiF. GhasemiJ.B. AzizianH. Design and synthesis of novel pyrazole-phenyl semicarbazone derivatives as potential α-glucosidase inhibitor: Kinetics and molecular dynamics simulation study.Int. J. Biol. Macromol.20211661082109510.1016/j.ijbiomac.2020.10.263 33157144
     [Google Scholar]
  63. CelebiogluH.U. ErdenY. HamurcuF. Cytotoxic effects, carbonic anhydrase isoenzymes, α-glycosidase and acetylcholinesterase inhibitory properties, and molecular docking studies of heteroatom-containing sulfonyl hydrazone derivatives.J. Biomol. Struct. Dyn.202139155539555010.1080/07391102.2020.1792345 32691677
     [Google Scholar]
  64. Meethale PallolathilR.R. RathikhaR. NithyabalajiR. SribalanR. Synthesis, characterization, in vitro and in silico studies of bis-hydrazone complexes derived from terephthalic dihydrazide.J. Mol. Struct.2021124213068310.1016/j.molstruc.2021.130683
     [Google Scholar]
  65. ZhangJ.H. XieH.X. LiY. Design, synthesis and biological evaluation of novel (E)-2-benzylidene-N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)hydrazine-1-carboxamide derivatives as α-glucosidase inhibitors.Bioorg. Med. Chem. Lett.20215212841310.1016/j.bmcl.2021.128413 34634473
     [Google Scholar]
  66. AzimiF. AzizianH. NajafiM. Design and synthesis of novel quinazolinone-pyrazole derivatives as potential α-glucosidase inhibitors: Structure-activity relationship, molecular modeling and kinetic study.Bioorg. Chem.202111410512710.1016/j.bioorg.2021.105127 34246971
     [Google Scholar]
  67. KarrouchiK. FettachS. AnouarE.H. Synthesis, crystal structure, DFT, α-glucosidase and α-amylase inhibition and molecular docking studies of (E)-N′-(4-chlorobenzylidene)-5-phenyl-1H-pyrazole-3-carbohydrazide.J. Mol. Struct.2021124513106710.1016/j.molstruc.2021.131067
     [Google Scholar]
  68. SundarramA. MurthyT.P. α-amylase production and applications: A review.J. Appl. Environ. Microbiol.201424166175
     [Google Scholar]
  69. TahaM. Tariq JavidM. ImranS. Synthesis and study of the α-amylase inhibitory potential of thiadiazole quinoline derivatives.Bioorg. Chem.20177417918610.1016/j.bioorg.2017.08.003 28826047
     [Google Scholar]
  70. ShahidpourS. PanahiF. YousefiR. NourisefatM. NabipoorM. Khalafi-NezhadA. Design and synthesis of new antidiabetic α-glucosidase and α-amylase inhibitors based on pyrimidine-fused heterocycles.Med. Chem. Res.20152473086309610.1007/s00044‑015‑1356‑2
     [Google Scholar]
  71. NawazM. TahaM. QureshiF. Structural elucidation, molecular docking, α-amylase and α-glucosidase inhibition studies of 5-amino-nicotinic acid derivatives.BMC Chem.20201414310.1186/s13065‑020‑00695‑1 32685927
     [Google Scholar]
  72. Al-AbdulbaqiM.A. TahaM. RahimF. Exploring diabetics II inhibitors based on benzodioxin derivatives, structure activity relationship, molecular docking and ADME property study.J. Mol. Struct.2024130613779710.1016/j.molstruc.2024.137797
     [Google Scholar]
  73. GhannayS. AldhafeeriB.S. AhmadI. Identification of dual-target isoxazolidine-isatin hybrids with antidiabetic potential: Design, synthesis, in vitro and multiscale molecular modeling approaches.Heliyon2024104e2591110.1016/j.heliyon.2024.e25911 38380049
     [Google Scholar]
  74. MehmoodH. AkhtarT. HaroonM. Synthesis of fluorinated hydrazinylthiazole derivatives: A virtual and experimental approach to diabetes management.ACS Omega2023812114331144610.1021/acsomega.3c00265 37008089
     [Google Scholar]
  75. KhanI. RehmanW. RahimF. Synthesis and in vitro α-amylase and α-glucosidase dual inhibitory activities of 1,2,4-triazole-bearing bis-hydrazone derivatives and their molecular docking study.ACS Omega2023825225082252210.1021/acsomega.3c00702 37396210
     [Google Scholar]
  76. HassanA.S. MorsyN.M. AboulthanaW.M. RagabA. Exploring novel derivatives of isatin-based Schiff bases as multi-target agents: Design, synthesis, in vitro biological evaluation, and in silico ADMET analysis with molecular modeling simulations.RSC Advances202313149281930310.1039/D3RA00297G 36950709
     [Google Scholar]
  77. El AshryE.S.H. FarahatM.M.K. AwadL.F. New 4-(arylidene)amino-1,2,4-traizole-5-thiol derivatives and their acyclo thioglycosides as α-glucosidase and α-amylase inhibitors: Design, synthesis, and molecular modelling studies.J. Mol. Struct.2022125913273310.1016/j.molstruc.2022.132733
     [Google Scholar]
  78. KhanS. RahimF. RehmanW. New benzoxazole-based sulphonamide hybrids analogs as potent inhibitors of α-amylase and α-glucosidase: Synthesis and in vitro evaluation along with in silico study.Arab. J. Chem.2022151210434110.1016/j.arabjc.2022.104341
     [Google Scholar]
  79. HussainR. ShahM. IqbalS. Molecular iodine-promoted oxidative cyclization for the synthesis of 1,3,4-thiadiazole-fused- [1,2,4]-thiadiazole incorporating 1,4-benzodioxine moiety as potent inhibitors of α-amylase and α-glucosidase: In vitro and in silico study.Front Chem.202210102331610.3389/fchem.2022.1023316 36339037
     [Google Scholar]
  80. MehmoodH. HaroonM. AkhtarT. WoodwardS. AndleebH. Synthesis and molecular docking studies of 5-acetyl-2-(arylidenehydrazin-1-yl)-4-methyl-1,3-thiazoles as α-amylase inhibitors.J. Mol. Struct.2022125013180710.1016/j.molstruc.2021.131807
     [Google Scholar]
  81. KhanS. UllahH. RahimF. New thiazole-based thiazolidinone derivatives: Synthesis, in vitro α-amylase, α-glucosidase activities and silico molecular docking study.Chemical Data Collections20224210096710.1016/j.cdc.2022.100967
     [Google Scholar]
  82. HussainR. IqbalS. ShahM. Synthesis of novel benzimidazole-based thiazole derivatives as multipotent inhibitors of α-amylase and α-glucosidase: In vitro evaluation along with molecular docking study.Molecules20222719645710.3390/molecules27196457 36234994
     [Google Scholar]
  83. HussainS. TahaM. RahimF. Synthesis of benzimidazole derivatives as potent inhibitors for α-amylase and their molecular docking study in management of type-II diabetes.J. Mol. Struct.2021123213002910.1016/j.molstruc.2021.130029
     [Google Scholar]
  84. AertgeertsK. YeS. TennantM.G. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation.Protein Sci.200413241242110.1110/ps.03460604 14718659
     [Google Scholar]
  85. ChinenA.B. GuanC.M. FerrerJ.R. BarnabyS.N. MerkelT.J. MirkinC.A. Nanoparticle probes for the detection of cancer biomarkers, cells, and tissues by fluorescence.Chem. Rev.201511519105301057410.1021/acs.chemrev.5b00321 26313138
     [Google Scholar]
  86. KirbyM. YuD.M.T. O’connorS. GorrellM.D. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.Clin. Sci. (Lond.)20101181314110.1042/CS20090047 19780719
     [Google Scholar]
  87. MakrilakisK. The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect.Int. J. Environ. Res. Public Health20191615272010.3390/ijerph16152720 31366085
     [Google Scholar]
  88. KasinaS.V. BaradhiK.M. Dipeptidyl Peptidase IV (DPP IV) Inhibitors.In: StatPearls.StatPearls Publishing2023
     [Google Scholar]
  89. SinghA.K. YadavD. SharmaN. JinJ.O. Dipeptidyl Peptidase (DPP)-IV inhibitors with antioxidant potential isolated from natural sources: A novel approach for the management of diabetes.Pharmaceuticals (Basel)202114658610.3390/ph14060586 34207217
     [Google Scholar]
  90. KawalecP. MikrutA. ŁopuchS. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.Diabetes Metab. Res. Rev.201430426928310.1002/dmrr.2494 24829965
     [Google Scholar]
  91. GallwitzB. Clinical use of DPP-4 inhibitors.Front. Endocrinol. (Lausanne)20191038910.3389/fendo.2019.00389 31275246
     [Google Scholar]
  92. SharmaA. PaliwalG. UpadhyayN. TiwariA. Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment.J. Diabetes Metab. Disord.20151418
     [Google Scholar]
  93. InzucchiS.E. BergenstalR.M. BuseJ.B. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Diabetes Care201538114014910.2337/dc14‑2441 25538310
     [Google Scholar]
  94. DoupisJ. Linagliptin: From bench to bedside.Drug Des. Devel. Ther.2014843144610.2147/DDDT.S59523 24851042
     [Google Scholar]
  95. DeaconC.F. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.Nat. Rev. Endocrinol.2020161164265310.1038/s41574‑020‑0399‑8 32929230
     [Google Scholar]
  96. DludlaP.V. NkambuleB.B. TianoL. LouwJ. JastrochM. Mazibuko-MbejeS.E. Uncoupling proteins as a therapeutic target to protect the diabetic heart.Pharmacol. Res.2018137112410.1016/j.phrs.2018.09.013 30223086
     [Google Scholar]
  97. KalraS. DasA.K. PriyaG. Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel.J. Family Med. Prim. Care20209115450545710.4103/jfmpc.jfmpc_843_20 33532378
     [Google Scholar]
  98. PetersonsC.J. Second steps in managing type 2 diabetes.Aust. Prescr.201841514114410.18773/austprescr.2018.043 30410209
     [Google Scholar]
  99. KushwahaR.N. HaqW. KattiS.B. Discovery of 17 gliptins in 17-years of research for the treatment of type 2 diabetes: A synthetic overview.Chem. Biol.20144137162
     [Google Scholar]
  100. MathurV. AlamO. SiddiquiN. Insight into structure activity relationship of DPP-4 inhibitors for development of antidiabetic agents.Molecules20232815586010.3390/molecules28155860 37570832
     [Google Scholar]
  101. JadhavP.B. JadhavS.B. ZehraviM. Virtual screening, synthesis, and biological evaluation of some carbohydrazide derivatives as potential DPP-IV inhibitors.Molecules202228114910.3390/molecules28010149 36615348
     [Google Scholar]
  102. ArshiaF.S. FayyazS. ShaikhM. KhanK.M. ChoudharyM.I. Anti-glycemic potential of benzophenone thio/semicarbazone derivatives: Synthesis, enzyme inhibition and ligand docking studies.J. Biomol. Struct. Dyn.202240167339735010.1080/07391102.2021.1897045 33769204
     [Google Scholar]
  103. Abu KhalafR. AwadM. Al-EssaL. Discovery, synthesis and in combo studies of Schiff’s bases as promising dipeptidyl peptidase-IV inhibitors.Mol. Divers.2021202113 34553298
     [Google Scholar]
/content/journals/cpd/10.2174/0113816128339161240913055034
Loading
A Captivating Potential of Schiff Bases Derivatives for Antidiabetic Activity
Curr. Pharm. Des. 31, 37 (2025); https://doi.org/10.2174/0113816128339161240913055034
/content/journals/cpd/10.2174/0113816128339161240913055034
/content/journals/cpd/10.2174/0113816128339161240913055034
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): amylase; Antidiabetic drugs; diabetes; glucosidase; organic compounds; Schiff bases

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test